Treatment of B-lymphoma by targeting protein degradation
Grant number: 1026988 | Funding period: 2012 - 2014
B-cell lymphoma is the most common type blood cancer diagnosed in Australia, and Australia's fifth most common cancer. Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a leading cause of cancer-related mortality. Our pilot studies reveal a novel approach to treatment of B-cell lymphoma by inhibiting an enzyme that destroys our natural mechanism of defense against cancer. In this study we will test the efficacy of this novel treatment.
Related publications (8)
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
Kamil Wolyniec, Jake Shortt, Elisa de Stanchina, Yaara Levav-Cohen, Osnat Alsheich-Bartok, Igal Louria-Hayon, Vincent Corneille, Beena Kumar, Simone J Woods, Stephen Opat, Ricky W Johnstone, Clare L Scott, David Segal, Pier Paolo Pandolfi, Stephen Fox, Andreas Strasser, Yong-Hui Jiang, Scott W Lowe, Sue Haupt, Ygal Haupt